Medical/Pharmaceuticals
How to Care for Caregivers? NCCN Debuts Essential Guide for Supporting Loved Ones with Cancer
New, free book offers simple but empowering information on how to care for people with cancer while also caring for yourself. PLYMOUTH MEETING, Pa., Oct. 27, 2026 /PRNewswire/ -- Today, the National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers in the United States ...
2026-10-27 20:07
2941
New Indication Application for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Accepted for Review by NMPA
* This is the seventh indication application for sacituzumab tirumotecan (sac-TMT) and the second application for the ADC plus IO combination regimen of sac-TMT plus pembrolizumab accepted for review. * The Phase III OptiTROP-Lung06 study supporting this application showed that sac-TMT plus p...
2026-10-27 19:10
3892
Hengrui Pharma Reports Steady Growth in the First Nine Months of 2026
SHANGHAI, Oct. 27, 2026 /PRNewswire/ -- Hengrui Pharma ("Hengrui" or "the Company") today announced its financial results for the first nine months of 2026. During this period, Hengrui reported revenue of RMB24.41 billion, representing a year-over-year increase of 5.26%. Product sales revenue was...
2026-10-27 18:04
3906
Natus Celebrates Grand Opening of Suzhou Facility - Advancing Innovation in China, for China
Local development and manufacturing bring Natus neurodiagnostic expertise closer to clinicians and patients across China SUZHOU, China, Oct. 27, 2026 /PRNewswire/ -- Natus Medical Incorporated, the world's largest pure-play neurodiagnostic company, today celebrated the grand opening of its devel...
2026-10-27 11:13
3138
Asia-Pacific's First Whole-Body Clinical 5T MRI System Installed in Vietnam, Advancing a New Regional High-Field MRI Center of Excellence
HANOI, Vietnam, Oct. 27, 2026 /PRNewswire/ -- On October 26, 2026, United Imaging Healthcare's uMR Jupiter 5T MRI system was officially introduced at Hanoi Medical University Hospital (HMUH), marking the arrival ofthe first whole-body clinical 5T MRI in the Asia-Pacificregion (outside China). The...
2026-10-27 10:20
4907
MEPSGEN Launches NanoCalibur® Mini for Small-Volume Nanoparticle Formulation
* Automated system enables rapid, reproducible formulation screening with minimal sample consumption * Completes the NanoCalibur® Series (Mini, Lab, Pro, GMP), supporting a seamless scale-up path from early research to GMP manufacturing BOSTON, Oct. 26, 2026 /PRNewswire/ -- MEPSGEN US, Inc., ...
2026-10-26 22:00
2962
Insilico Medicine Reports 40% ORR at 130 mg for Pan-TEAD Inhibitor ISM6331 Designed Using Generative AI in Heavily Pretreated Mesothelioma at ESMO 2026
CAMBRIDGE, Mass., Oct. 26, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage generative AI–driven drug discovery company, today announced promising first-in-human Phase 1 data for ISM6331, its investigational oral pan-TEAD inhibitor designed using Chemistry42 gener...
2026-10-26 21:00
5563
TJ Biopharma Doses First Patient in Phase 1 Trial of TJ-C64B, a CLDN6x4-1BB Bispecific Antibody for CLDN6-Positive Solid Tumors
- TJ-C64B is an internally developed CLDN6 × 4-1BB bispecific antibody for which TJ Biopharma retains global rights, and is among the leading programs in this class globally - First patient dosing marks a key milestone for TJ Biopharma's next-generation innovation pipeline HANGZHOU, China, Oct....
2026-10-26 20:00
3815
Final OS Analysis Results of Phase III OptiTROP-Breast01 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in Annals of Oncology
CHENGDU, China, Oct. 26, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, the results of the final overall survival (OS) analysis o...
2026-10-26 18:33
3976
CityUHK researchers reveal how fructose can suppress liver cancer, opening a new therapeutic avenue
HONG KONG, Oct. 26, 2026 /PRNewswire/ -- Fructose is an important nutrient, which despite having a chemical structure very similar to that of glucose, is metabolised very differently in the body. Research into fructose metabolism and its regulation of metabolism in the human body has in recent ye...
2026-10-26 17:50
2543
WuXi AppTec Delivers Strong Q1-Q3 2026 Results and Further Raises Full-Year Guidance, Driven by Greater Success of Multiple Customers' Products and CRDMO Model
SHANGHAI, Oct. 26, 2026 /PRNewswire/ -- WuXi AppTec (Stock Codes: 603259.SH / 2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced financial results for the first three quarters ending September 30, 2026 ("Reporting Peri...
2026-10-26 17:25
6046
Innovent Announces NMPA Acceptance of a New Indication Application of Sintilimab for the Treatment of Advanced Melanoma
SAN FRANCISCO and SUZHOU, China, Oct. 26, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major dise...
2026-10-26 17:18
2975
Tencent Cloud Enhances Telehealth Experiences for Care, Safeguarding Every Doctor-Patient Connection
HONG KONG, Oct. 26, 2026 /PRNewswire/ -- Tencent Cloud, the cloud business of global technology company Tencent, today announced its collaboration with Care, one of Singapore's leading and most trusted telehealth digital solutions providers, to strengthen the quality and reliability of virtual he...
2026-10-26 16:57
1929
CStone Announces Major Clinical Validation Milestone for CS2009 at ESMO 2026: Data from More Than 300 Patients Support Mechanism, Safety and Broad Antitumor Activity
CS2009, an Innovative PD-1/VEGF/CTLA-4 trispecific antibody, demonstrates a differentiated profile through synergistic triple-pathway targeting, favorable tolerability and encouraging efficacy across multiple solid tumors Highlights * Three pillars of clinical validation: Clinical data from ov...
2026-10-26 16:45
2208
111, Inc. Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee
SHANGHAI, Oct. 26, 2026 /PRNewswire/ -- 111, Inc. ( "111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company in China, announced today that the special committee (the "Special Committee"), comprising three independent directors, Mr. Jian Sun, who is the chairman of...
2026-10-26 16:00
2958
ESMO 2026 | Professors Jie Wang, Zhijie Wang and Jianchun Duan's Team Reports 95.2% Disease Control With LK101 Combination Maintenance Therapy in Advanced NSCLC
BEIJING, Oct. 25, 2026 /PRNewswire/ -- On October 24, 2026, in Madrid, Spain, the team of Professors Jie Wang, Zhijie Wang and Jianchun Duan at the Cancer Hospital, Chinese Academy of Medical Sciences, presented Phase 1b/2a results in a Rapid Oral session at ESMO Congress 2026. The study evaluate...
2026-10-26 11:27
3583
Results of CARsgen's Satri-cel for Adjuvant Treatment for Gastric Cancer Presented at ESMO Congress 2026
SHANGHAI, Oct. 25, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the preliminary positive research results of the investigator-initiated trial (CT041-CG4010, NCT06857786) in China o...
2026-10-26 08:30
6490
Ascletis Announces FDA IND Submission of ASC39, an Oral Small Molecule Selective Amylin Receptor Agonist for the Treatment of Obesity
- ASC39, an oral small molecule selective amylin receptor agonist, demonstrated eloralintide-like amylin selectivity and efficacy in preclinical models. - ASC39 demonstrated eloralintide-like selectivity for human amylin 1 receptor (hAMY1R) over human calcitonin receptor (hCTR) (40-fold), support...
2026-10-26 08:10
6876
2026 ESMO | Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928, a PD-1/Alpha-Biased IL-2 Bispecific Fusion Protein
* The data showcased are from three Phase 1b clinical studies of IBI363/TAK-928 in first-line NSCLC, first-line G/GEJA, and immunotherapy-resistant lung adenocarcinoma, further supporting its potential clinical value across treatment settings. SAN FRANCISCO and SUZHOU, China, Oct. 25, 2026 /PR...
2026-10-26 08:00
4913
Antengene Presents Latest Clinical Results for ATG-022 and ATG-037 at ESMO 2026
SHANGHAI and HONG KONG, Oct. 26, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...
2026-10-26 08:00
2989
Week's Top Stories
Most Reposted
TD Brings its Global Asset Management Businesses Under One Name
[Picked up by 1169 media titles]
2026-11-02 20:00OceanaGold Reports Third Quarter 2026 Results
[Picked up by 1130 media titles]
2026-11-05 06:52Algolia Powers Orange with AI Agents for Billing Support: NYSE Content Update
[Picked up by 1118 media titles]
2026-11-06 22:06
Overstory Launches Integrated AI Platform to Deliver First Living Model of Grid Risk
[Picked up by 1082 media titles]
2026-11-03 22:00NYSE Chair Sharon Bowen Earns Lifetime Achievement Award: NYSE Content Update
[Picked up by 1073 media titles]
2026-11-05 22:05
Most Read
1B views since June: Coda and TikTok Gaming turn content into commerce
2026-11-02 09:35
64029
Airbrush Upgrades AI Image Enhancer With 16K Output and Batch Processing for Up to 50 Images
2026-11-03 02:00
60884
iQIYI Launches China's First AI Film Studio in Shanghai, with Inaugural Title "Cop in Trouble" in Production
2026-11-02 09:52
57146
Korean Derma Skincare Brand MDP+ Launches at Nordstrom
2026-11-03 00:30
26632
